Related Experiment Video
Updated: Mar 30, 2026

10:04
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
19.4K
Tuberculosis of the Cheek: A Rare Presentation
1From the Department of Pedodontics & Preventive Dentistry, Post Graduate Institute of Dental Sciences, Rohtak.
The Journal of Clinical Pediatric Dentistry
|November 10, 2015
Summary
Primary tuberculosis (TB) in children can present unusually in the mouth, even before lung symptoms appear. Early diagnosis and treatment of oral TB lesions lead to full recovery.
Area of Science:
- Oral Medicine
- Pediatric Infectious Diseases
- Mycobacterial Infections
Background:
- Tuberculosis (TB) commonly affects the lungs, with oral manifestations being rare and often misdiagnosed.
- Atypical oral lesions of tuberculosis can precede systemic symptoms, complicating early detection.
- Primary and secondary oral TB lesions require careful clinical evaluation due to varied presentations.
Observation:
- A 4-year-old female child presented with a primary tuberculosis lesion in an uncommon oral location: the cheek.
- The oral lesion was the initial presenting sign, without apparent systemic symptoms at the time of diagnosis.
- The lesion's atypical presentation on the cheek posed diagnostic challenges.
Findings:
- The case highlights primary tuberculosis manifesting as an isolated cheek lesion in a pediatric patient.
- Diagnostic confirmation was followed by prompt initiation of antitubercular therapy.
- Complete resolution of the cheek swelling was achieved within six months of treatment.
Implications:
- This case underscores the importance of considering tuberculosis in pediatric patients with unexplained oral lesions, even in atypical sites.
- Early recognition and management of oral tuberculosis are crucial for favorable outcomes and preventing disease progression.
- Clinicians should maintain a high index of suspicion for oral tuberculosis, particularly when lesions present atypically or before systemic signs are evident.
Related Concept Videos
Pulmonary Tuberculosis I
1.4K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.4K
Pulmonary Tuberculosis V
864
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
864
Pulmonary Tuberculosis II
2.1K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.1K
Pulmonary Tuberculosis III
1.4K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
1.4K
Pulmonary Tuberculosis IV
704
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
704
Other Pulmonary Disorders
2.0K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
2.0K

